Ligand Pharmaceuticals Incorporated

LGND14 Dec 2024
Healthcare
$114.01
+0.03 (+2.94%)
Lowest Today
$113.67
Highest Today
$116.8
Today’s Open
$114.01
Prev. Close
$113.51
52 Week High
$129.9
52 Week Low
$65.84
To Invest in Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Incorporated

Healthcare
LGND14 Dec 2024
+0.03 (+2.94%)
1M
3M
6M
1Y
5Y
Low
$113.67
Day’s Range
High
$116.8
113.67
52 Week Low
$65.84
52-Week Range
52 Week High
$129.9
65.84
1 Day
-
1 Week
-6.86%
1 month return
-5.08%
3 month return
+10.84%
6 month return
+42.45%
1 Year return
+73.15%
3 Years return
+29.82%
5 Years return
+75.8%
10 Years return
-
Institutional Holdings
BlackRock Inc
15.2
Vanguard Group Inc
10.43
iShares Core S&P Small-Cap ETF
6.25
HHG PLC
5.34
Macquarie Group Ltd
4.7
State Street Corp
3.74
Dimensional Fund Advisors, Inc.
3.74

Market Status

Fundamentals
Market Cap
2274.25 mln
PB Ratio
2.7
PE Ratio
48.34
Enterprise Value
2061.96 mln
Total Assets
787.22 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
Organisation
Ligand Pharmaceuticals Incorporated
Employees
58
Industry
Biotechnology
CEO
Mr. Todd C. Davis Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step